Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021

Eloxx Pharmaceuticals Inc ELOX provided an enrollment update for the ongoing Phase 2 trial of ELX-02 to treat cystic fibrosis (CF) in patients with at least one G542X allele.
Based on enrollment to date, Eloxx expects to present data from the first four treatment arms in Q4 of 2021.
As of the end of June 2021, Eloxx has enrolled a sufficient number of patients to assess the biological activity of ELX-02.
ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene.
Recently, a fifth treatment arm was added to the program to evaluate the safety of ELX-02 in combination with Vertex Pharmaceuticals Incorporated's VRTX Kalydeco (ivacaftor), an FDA-approved CFTR potentiator for cystic fibrosis in patients with at least one mutation in their CF gene amenable to ivacaftor.
The Cystic Fibrosis Foundation partially funds the program.
The U.S. Food and Drug Administration has granted orphan drug designation for ELX-02 for the treatment of CF.
Price Action: ELOX shares are up 2.6% at $1.98 during the premarket session on the last check Wednesday.